Healing & recovery
BPC-157
Body Protection Compound-157 · stable gastric pentadecapeptide
The most-searched non-GLP-1 peptide — search interest rose roughly 12x from 2023 to 2026 — and the central case in the 2026 compounding-reclassification news. Widely promoted for injury recovery despite thin evidence.
Evidence
Danimal-only
Status
Removed from Cat 2 · pending PCACas of 2026-06
Approval
Not approved
Category
Healing & recovery
Route
Subcutaneous · Intramuscular · Oral
Demand rank
#4 most-searched
01Dosing & Protocol
Typical · reference only
~250-500 mcg/day SC (community); local vs systemic; oral capsules for gut
Titration
Start ~200-250 mcg/day, increase toward 500 mcg if tolerated (no clinical basis)
Reconstitution — illustrative, not a recommendation
10 mg vial + 2 mL BAC = 5000 mcg/mL; 250 mcg = 5 U, 500 mcg = 10 U on U-100. NOTE mg vs mcg = 1000x hazard (human studies dosed in mg).
Reconstitution calculatorlive tool
5units
on a U-100 syringedraw to the 5 mark
Concentration5 mg/mL
Draw volume0.05 mL
Illustrative, not a recommendation. mg vs mcg confusion drives 5–1000× overdoses — always recompute for your own vial and syringe.
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Removal != legal to compound != FDA-approved. WADA S0 prohibited; DoD-prohibited.
Status
Removed from Cat 2 · pending PCAC
503A bulks
Not on the bulks list
Category 2
Removed from 503A Category 2 ~22 Apr 2026 (nomination withdrawn)
PCAC review
2026-07-23/24
WADA
Prohibited
03Evidence — the honest read
What the evidence actually shows
Animal-heavy; only ~3 tiny uncontrolled human studies (~28 subjects total); no RCTs. 2025 review: 'should not be recommended for clinical use.' Headline efficacy figures are marketing.
04Safety
Contraindications
- Active/prior cancer (pro-angiogenic; precautionary)
- Pregnancyhard stop
- WADA-tested athletes/military
- Anticoagulant users (uncharacterized - clinician oversight)
Key interactions
- Anticoagulants - direction uncertain (rat data REDUCED bleeding; do not assert either way)
Serious signals
- Unknown long-term safety
- Theoretical angiogenesis/cancer concern
- Anecdotal anxiety/anhedonia reports (STAT, Feb 2026)
Monitoring
No validated cadence; cancer screening + exclude active malignancy (harm-reduction).
05Related in Healing & recovery
06Sources
The primary sources behind this monograph — each opens the registry so you can verify the claim yourself. Last verified 2026-06-13.
Peer-reviewedCurrent Reviews in Musculoskeletal Medicine 2025Evidence — peer-reviewed studyHow we source & verify — the full method →Beyond these primaries, every monograph is distilled from TrackurStack’s research dossier — 584 de-duplicated sources across 4 research iterations, adversarially verified against primary sources.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: med-high (science) / low (dosing)